Corina Lorz

Dr. Corina Lorz

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Oral Oncology
Verified
Journal Article
Closed access
RGRamon Garcia-Escudero
Ramon Garcia-Escudero
CSCarmen Segrelles
Carmen Segrelles
MDMarta Dueñas
Marta Dueñas
MPMaría Pombo
María Pombo
CBClaudio Ballestín
Claudio Ballestín
CLCorina Lorz
Corina Lorz

3 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KSKarla Santos
Karla Santos
CSCarmen Segrelles
Carmen Segrelles
CLCorina Lorz
Corina Lorz
Head and neck cancer affects the upper aerodigestive tract and is the sixth leading cancer worldwide by incidence and the seventh by cause of death. Despite significant advances in surgery and chemotherapy, molecularly targeted therapeutic options for this type of cancer are scarce and long term survival rates remain low. Recently, comprehensive genomic studies have highlighted the most commonly altered genes and signaling pathways in this cancer. The Hippo-YAP pathway has been identified as a key oncogenic pathway in multiple tumors. Expression of genes controlled by the Hippo downstream transcriptional coactivators YAP (Yes-associated protein 1) and TAZ (WWTR1, WW domain containing transcription regulator 1) is widely deregulated in human cancer including head and neck squamous cell carcinoma (HNSCC). Interestingly, YAP/TAZ signaling might not be as essential for the normal homeostasis of adult tissues as for oncogenic growth, altogether making the pathway an amenable therapeutic target in cancer. Recent advances in the role of Hippo-YAP pathway in HNSCC have provided evidence that genetic alterations frequent in this type of cancer such as PIK3CA (phosphatidylinositide 3-kinase catalytic subunit alpha) overexpression or FAT1 (FAT atypical cadherin 1) functional loss can result in YAP activation. We discuss current therapeutic options targeting this pathway which are currently in use for other tumor types.

1 November 2018 in Oral Oncology
Verified
Journal Article
Closed access
CSCarmen Segrelles
Carmen Segrelles
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio
CLCorina Lorz
Corina Lorz

1 June 2021 in Oral Oncology
Verified
Journal Article
Closed access
CVCarmen Vallina
Carmen Vallina
RLRosa María López-Pintor
Rosa María López-Pintor
JGJosé González-Serrano
José González-Serrano
JVJuan Carlos De Vicente
Juan Carlos De Vicente
GHGonzalo Hernández
Gonzalo Hernández
CLCorina Lorz
Corina Lorz

7 February 2014 in Stem Cells
Verified
Journal Article
Open access
PDF file
CSCarmen Segrelles
Carmen Segrelles
RGRamon Garcia-Escudero
Ramon Garcia-Escudero
MGMarina I. Garin
Marina I. Garin
JAJuan F. Aranda
Juan F. Aranda
PHPilar Hernández
Pilar Hernández
CLCorina Lorz
Corina Lorz
Hair follicle stem cells (HF‐SCs) alternate between periods of quiescence and proliferation, to finally differentiate into all the cell types that constitute the hair follicle. Also, they have been recently identified as cells of origin in skin cancer. HF‐SCs localize in a precise region of the hair follicle, the bulge, and molecular markers for this population have been established. Thus, HF‐SCs are good model to study the potential role of oncogenic activations on SC physiology. Expression of a permanently active form of Akt (myrAkt) in basal cells leads to Akt hyperactivation specifically in the CD34+Itga6H population. This activation causes bulge stem cells to exit from quiescence increasing their response to proliferative stimuli and affecting some functions such as cell migration. HF‐SC identity upon Akt activation is preserved; in this sense, increased proliferation does not result in stem cell exhaustion with age suggesting that Akt activation does not affect self‐renewal an important aspect for normal tissue maintenance and cancer development. Genome‐wide transcriptome analysis of HF‐SC isolated from myrAkt and wild‐type epidermis underscores changes in metabolic pathways characteristic of cancer cells. These differences manifest during a two‐step carcinogenesis protocol in which Akt activation in HF‐SCs results in increased tumor development and malignant transformation. Stem Cells 2014;32:1917–1928

1 January 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
RGRamon Garcia-Escudero
Ramon Garcia-Escudero
AMAna B Martínez-Cruz
Ana B Martínez-Cruz
MSMirentxu Santos
Mirentxu Santos
CLCorina Lorz
Corina Lorz
CSCarmen Segrelles
Carmen Segrelles
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio
The epidermal specific ablation of Trp53 gene leads to the spontaneous development of aggressive tumors in mice through a process that is accelerated by the simultaneous ablation of Rb gene. Since alterations of p53-dependent pathway are common hallmarks of aggressive, poor prognostic human cancers, these mouse models can recapitulate the molecular features of some of these human malignancies.